Drug Trial Radar · NCT00805194
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Dec 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,314
Actual
Start
Dec 3, 2008
Primary completion
Nov 2, 2010
Study completion Nov 13, 2017
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Dec 9, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
placebo plus docetaxelDrug
placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
BIBF 1120 plus docetaxelDrug
BIBF 1120 2 times daily along with standard therapy of docetaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) as Assessed by Central Independent ReviewTime frame: From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)
Locations
210 sites in 27 countries. Site status is shown where the registry gives one.
LKH-Univ. Hospital Graz
Graz, Austria
KH St. Vinzenz, Zams, Int. Abtlg.
Kufstein, Austria
AKH d. Stadt Linz, Pulmologie
Linz, Austria
Bobruisk Inter-distict
Babruysk, Belarus
Brest Regional Clinical
Brest Region, Belarus
Gomel Regional Clinical
Homyel, Belarus
Public Health Inst. Minsk City Clinical Oncology Dispensary
Minsk, Belarus
Scientific Research Minsk
Minsk Region, Belarus
Mogilov Regional Oncological Dispensary
Mogilev, Belarus
Vitebsk Regional Clinical Oncology Dispensary
Vitebsk, Belarus
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Liège - HOSP CHR de la Citadelle
Liège, Belgium
Multiprofile Hospital for Active Treatment
Gabrovo, Bulgaria
Univ.Multiprofile Hospital "Dr. Georgy Stranski" EAD, Pleven
Pleven, Bulgaria
District Oncology Dispensary Plovdiv
Plovdiv, Bulgaria
Interdistrict Oncology Dispensary, Ruse
Rousse, Bulgaria
District Oncology Dispensary Shumen
Shumen, Bulgaria
Specialized Hospital for Active Treatment in Oncolcogy
Sofia, Bulgaria
307 Hospital of PLA
Beijing, China
Jilin Province Cancer Hospital
Changchun, China
First Hospital of Jilin University
Changchun, China
West China Hospital
Chengdu, China
Southwest Hospital
Chongqing, China
First Affiliated Hospital of Dalian Medical University
Dalian, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, China
Fujian Provincial Tumor Hospital
Fujian, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Guangdong General Hospital
Guangzhou, China
Sir Run Run Shaw Hospital
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
The Third Affiliated Hospital of Harbin Medical University
Harbin, China
the 81th Hospital of PLA
Nanjing, China
Jiangsu Cancer Hospital
Nanjing, China
Shanghai Chest Hospital
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
Tongji Hospital, Tongji University
Wuhan, China
Zhongshan Hospital Fudan University
Xuhui Area, Shanghai, China
Clinical Hospital Centar Sestre Milosrdnice
Zagreb, Croatia
UHC Zagreb
Zagreb, Croatia
Showing 40 of 210 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.